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It is widely accepted that the conversion of the soluble, nontoxic amyloid β-protein (Aβ) monomer to aggregated toxic Aβ rich in
β-sheetstructuresiscentraltothedevelopmentofAlzheimer’sdisease.However,themechanismoftheabnormalaggregationofAβ
in vivo is not well understood. Accumulating evidence suggests that lipid rafts (microdomains) in membranes mainly composed
of sphingolipids (gangliosides and sphingomyelin) and cholesterol play a pivotal role in this process. This paper summarizes the
molecular mechanisms by which Aβ aggregates on membranes containing ganglioside clusters, forming amyloid ﬁbrils. Notably,
the toxicity and physicochemical properties of the ﬁbrils are diﬀerent from those of Aβ amyloids formed in solution. Furthermore,
diﬀerences between Aβ-(1–40) and Aβ-(1–42) in membrane interaction and amyloidogenesis are also emphasized.
1.Introduction
It is widely accepted that the amyloid β-protein (Aβ), which
exists in ﬁbrillar forms as a major component of senile
plaques, is central to the development of Alzheimer’s dis-
ease (AD) [1, 2]. The conversion of soluble, nontoxic Aβ
monomer to aggregated toxic Aβ rich in β-sheet structures
ignites the neurotoxic cascade(s) of Aβ [3]. The mechanism
of the abnormal aggregation of Aβ is not well understood.
The physiological concentration of Aβ in biological ﬂuids
(<10−8 M) [4] is much lower than the concentration (∼
1μM) above which Aβ-(1–40) spontaneously forms ﬁbrils
[5].Therefore,thereshouldbemechanismsthatfacilitatethe
abnormal aggregation of Aβ under pathological conditions.
Although clusterin (Apo J) [6]a n dZ n 2+ ions [7]w e r e
reported to facilitate the aggregation of Aβ more than a
decade ago, their aggregation-promoting mechanisms are
yet to be elucidated. In addition to these soluble factors,
Jarrett and Lansbury, Jr. suggested that Aβ ﬁbrillizes via a
nucleation-dependent polymerization mechanism and lipids
could act as heterogeneous seeds for the polymerization [8].
In 1995, Yanagisawa and colleagues discovered a speciﬁc
form of Aβ bound to monosialoganglioside GM1 (GM1)
in brains exhibiting early pathological changes of AD and
suggested that the GM1-bound form of Aβ may serve as a
seed for the formation of toxic amyloid aggregates/ﬁbrils [9].
We have been investigating the interaction of Aβ with
ganglioside-containing membranes for a dozen years and
found that not the uniformly distributed but the clustered
gangliosides mediate the formation of amyloid ﬁbrils by Aβ,
the toxicity and physicochemical properties of which are
diﬀerent from those of Aβ amyloids formed in solution.
This review article summarizes Aβ-ganglioside interaction
in detail, including latest ﬁndings that were not covered
in our previous reviews [10, 11]. Especially, diﬀerences
between Aβ-(1–40) and Aβ-(1–42) in membrane interaction
and amyloidogenesis are extensively discussed. Furthermore,
a link between Aβ aggregation and lipid metabolism is
emphasized. It will shed light on one of the initiation
processes of AD.
2. SpeciﬁcBindingofAβtoGangliosideClusters
Early studies indicated that Aβ-(1–40) associates with GM1
in egg yolk phosphatidylcholine (PC) vesicles only when the
GM1contentexceeds30% [12,13].ThethresholdGM1con-
tent is lowered in a sphingomyelin (SM)/cholesterol mixture
[13]. These ﬁndings suggest that GM1 molecules only in
a speciﬁc state can recognize Aβ. To reveal the underlying
mechanism, we systematically investigated the interaction of
dye-labeled-Aβ-(1–40) [14–16]a n d- A β-(1–42) [17]w i t h
membranes of various lipid compositions. The N-termini2 International Journal of Alzheimer’s Disease
Table 1: Parameters for the binding of DAC-Aβs to GM1/choleste-
rol/SM(1:1:1)L UVsat37 ◦C.
Aβ K (106 M−1)a xmax
b(Aβ/GM1, mol/mol) Ref.
DAC-Aβ-(1–42) 11.1 ± 2.4 0.0361 ± 0.0021 [17]
DAC-Aβ-(1–40) 8.6 ± 3.6 0.0313 ± 0.0041 [16]
DAC-Aβ-(1–28) 0.0184 ± 0.0007 0.0313c [16]
aBinding constant.
bMaximal value of x (bound Aβ per exofacial GM1, mol/mol).
cAssumed to be the same as that of DAC-Aβ-(1–40).
of Aβs were labeled with the 7-diethylaminocoumarin-3-
carbonyl group (DAC-Aβ). DAC-Aβ is useful for ﬂuoro-
metrically monitoring protein-lipid interactions, because
a signiﬁcant blue shift and an enhancement in intensity
are induced by a change in polarity upon membrane
binding. DAC-Aβs do not bind to major membrane lipids,
including electrically neutral PC, SM, cholesterol, negatively
charged phosphatidylserine, and phosphatidylglycerol under
physiological conditions. On the other hand, the proteins
exhibit similar high aﬃnity (binding constant ∼107 M−1)
for raft-like membranes composed of GM1, cholesterol, and
SM [14, 15]. DAC-Aβ-(1–28) also has a weak aﬃnity for
the membrane [16]. Binding parameters are summarized
in Table 1.D A C - A β-(1–40) also binds to other gangliosides
(GD1a, GD1b, GT1b, and asialo GM1) and lactosyl ceramide
in raft-like membranes with higher aﬃnity for lipids having
larger sugar chains [15, 16]. We have proposed that Aβs
speciﬁcally bind to ganglioside clusters because a GM1
cluster is formed in GM1/SM/cholesterol membranes but
not in GM1/PC membranes. The clustering is facilitated by
cholesterol [14].
3. Fibrillizationby Aβ on Ganglioside Clusters
Aβ-(1–40) bound to ganglioside clusters assumes diﬀerent
conformations depending on the protein density on the
membrane. Circular dichroism measurements revealed that
the protein forms an α-helix-rich structure at lower protein-
to-ganglioside ratios (≤0.025) whereas it changes its confor-
mation to a β-sheet-rich structure at higher ratios (≥0.05)
[14, 15]. Aβ-(1–42) also undergoes similar conformational
changes [17]. Only the β-sheet form facilitates amyloidogen-
esis by Aβ-(1–40) [15, 18–20].
Despite very similar initial protein-ganglioside interac-
tion, that is, the binding behavior and the α-helix-to-β-
sheet conformational change, a large diﬀerence was observed
in amyloidogenic activity (amount of amyloids formed
under certain conditions) between Aβ-(1–40) and Aβ-(1–
42) [17]. Aβs were incubated with GM1/cholesterol/SM
liposomes at a Aβ-to-GM1 ratio of 5, and the aggregation
of Aβ was monitored as an increase in ﬂuorescence of the
amyloid-speciﬁc dye thioﬂavin-T (Th-T) (Figure 1). Aβ-(1–
42) formed amyloids without a lag time at 5μM. In contrast,
Aβ-(1–40) at 5μM did not form amyloids, at least not in
12h. At a 10-fold higher concentration, Aβ-(1–40) started
to aggregate after a lag time of ∼2h. The eﬀectiveness of Aβ-
(1–42) in ﬁbrillogenesis is at least partly due to the fragility
0
T
h
-
T
ﬂ
u
o
r
e
s
c
e
n
c
e
(
a
.
u
.
)
20
40
60
0246
Time (h)
81 0 1 2
Figure 1: Aβ aggregation in the presence of raft-like liposomes.
Aβs( 5 μMo r5 0 μM) were incubated with GM1/cholesterol/SM
(1:1:1) small unilamellar vesicles at a GM1-to-Aβ ratio of 5 at
37◦C without agitation, and the aggregation was monitored by the
Th-Tassay.Symbols:circles,5μMAβ-(1–42);squares,5μMAβ-(1–
40); triangles, 50μMA β-(1–40). Data taken from [17].
of ﬁbrils, because the fragmentation greatly facilitates ﬁbril
growth [21] (see also Section 5). Other factors, such as
the rapid formation of seeds and/or elongation, may also
contribute to the diﬀerence.
Cell experiments also support the above mechanism of
Aβ-ganglioside interaction [22, 23]. Aβ-(1–42) was incu-
bated with neuronal rat pheochromocytoma PC12 cells.
Amyloids and gangliosides were detected by the amyloid-
speciﬁc dye Congo red and the ﬂuorescent-labeled cholera
toxin B subunit, respectively. Amyloids were selectively
formed on ganglioside-rich domains (Figure 2(a)). Deple-
tion of cholesterol, either by methyl-β-cyclodextrin or
the cholesterol synthesis inhibitor compactin, suppressed
the accumulation of Aβ. The amyloidogenic activity of
Aβ-(1–42) was again more than 10-fold that of Aβ-(1–
40) on human SH-SY5Y neuroblastoma cells expressing
gangliosides (Figure 2(b)). When cells were incubated with
5μMA β-(1–42), Congo red-positive spots appeared later
at 24h and became prominent with time. In contrast,
when cells were incubated with 5μMA β-(1–40), no ﬁbrils
were detected even after 72h. Incubation with a 10-fold
higher concentration of the protein, however, resulted in the
appearance of Congo red-positive spots at 48h.
4. Properties of Aβ Fibrils Formed on
GangliosideClusters
The Aβ ﬁbrils formed on ganglioside clusters (Mem-ﬁbrils)
are not identical to those formed in solution (Sol-ﬁbrils)
in terms of physicochemical properties and cytotoxicity
[20]. Transmission electron micrographs indicate that Mem-
ﬁbrils are typical nonbranched ﬁbrils (12.0 ± 0.7nm, width)
whereas Sol-ﬁbrils are thinner ﬁbrils or protoﬁlamentsInternational Journal of Alzheimer’s Disease 3
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Figure 2: Aβ aggregation on living neuronal cells. (a) Aβ-(1–42) (10μM) was incubated with PC12 cells for 24h at 37◦C. The distribution
of GM1 was detected by using the cholera toxin B subunit conjugated with Alexa Fluor 647 dye (CTX-B, left). Amyloids were visualized by
the amyloid-speciﬁc dye Congo red (middle). The merging of the two images shows that amyloids were formed in the vicinity of GM1-rich
domains of cell membranes (right). Data taken from [10]. (B) Ganglioside-expressing SH-SY5Y cells were incubated with 5μMA β-(1–42)
(top), 5μMA β-(1–40) (middle), or 50μMA β-(1–40) (bottom) for 0.5, 18, 24, 48, or 72h, and the formation of amyloids was detected with
Congo red. The conditions under which cell death was observed are framed in green. Data taken from [17].
(6.7 ± 1.3nm, width), and the protoﬁlaments associate
laterally and twist into rope-like ﬁbrils (14.5 ± 0.9nm,
width). The surface hydrophobicity of Mem-ﬁbrils as esti-
mated by the binding of 1-anilinonaphthalene-8-sulfonate
(ANS)islargerthanthatofSol-ﬁbrils(Figure 3(a)),therefore
Mem-ﬁbrils exhibit signiﬁcantly stronger binding to cell
membranes than Sol-ﬁbrils (Figure 3(b)). Consequently,
Mem-ﬁbrils are cytotoxic whereas Sol-ﬁbrils are much less
toxic (Figure 3(c)). Recently, a correlation between ANS-
binding and cytotoxicity was reported for various amyloid
species [24].
The structure of Mem-ﬁbrils is suggested to be diﬀerent
from that of Sol-ﬁbrils, in which the cross-β unit is a double-
layered structure, with in-resister parallel β-sheets formed by
residues 12–24 and 30–40 [25]. The amide I spectrum of the
formershows,inaddition to amajor peakaround1630cm−1
characteristic of a β-sheet, a weak peak at 1695cm−1 whereas
that of the latter shows a peak around 1660cm−1 [26].
5.Mechanismof Cytotoxicityby Aβ Fibrils
Formed on GangliosideClusters
The mechanisms of Aβ-induced cytotoxicity have been
controversial. Aβ ﬁbrils were reported to trigger functional
disorder in neuronal cells and cell death [27–31]w h e r e a s
soluble Aβ oligomers have been proposed to play a pivotal
role in the onset of AD [6, 28, 32–39]. To obtain an insight
into the cytotoxic mechanism of Aβ, we established a
multistaining visualization method using unlabeled Aβsa n d
antibodies [17] in contrast to conventional methods using
ﬂuorophore-labeled proteins [23, 40]. The accumulation
of Aβ, the formation of amyloid ﬁbrils, the formation of
oligomers, and cell viability were visualized using the Aβ
monoclonal antibody 6E10, the amyloid-staining dye Congo
red [22], the antioligomer antibody A11 [34], and calcein
acetoxymethyl, respectively. Cell death was detected after the
signiﬁcant accumulation of ﬁbrils (Figure 2(b)) and no A11-
positive spot was detected, suggesting that ﬁbril-induced
physicochemical stress, such as the induction of a negative
curvature [13] or membrane deformation upon ﬁbril
growth [41], leads to cytotoxicity. A11-positive oligomers
were not formed in the ﬁbrillization with GM1-containing
liposomes either [20]. It should be noted, however, that at
certain GM1 contents GM1-liposomes generate toxic soluble
Aβ-(1–40) oligomers [42]. For both Aβs, similar levels of
ﬁbrilswererequiredforcytotoxicity(Figure 2(b)),indicating
that the ﬁbrils possess comparable intrinsic toxicity. The
ﬁbrillization process and cytotoxicity can be eﬀectively4 International Journal of Alzheimer’s Disease
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Figure 3: Comparison between Mem-ﬁbrils and Sol-ﬁbrils. Data taken from [20]. (a) Fluorescence spectra of ANS (5.0μM) in PBS were
measured in the absence or presence of Mem-ﬁbrils and Sol-ﬁbrils of Aβ-(1–40) (2.5μM) with an excitation wavelength of 350nm. The
bindingofthedyetoahydrophobicsurfaceresultsinanenhancementinﬂuorescenceintensity.(b)Aβ-(1–40)ﬁbrils(25μM)wereincubated
with NGF-diﬀerentiated PC12 cells for 30min. Binding of Aβ-(1–40) ﬁbrils to cells was evaluated by ﬂuorescence intensity of Congo red
per cell (mean ± S.E.; n ∼ 100, ∗P<. 001). (c) Aβ-(1–40) ﬁbrils (25μM) were incubated with NGF-diﬀerentiated PC12 cells for 24h.
Aβ cytotoxicity was estimated with ﬂuorescence intensity of the live cell marker calcein (mean ± S.E.; n = 6; ∗P<. 001 against vehicle
treatment).
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Figure 4: Visualization of amyloid ﬁbrils formed on cell membranes using TIRFM. SH-SY5Y cells were treated with 50μMA β-(1–40) ((a),
(b)) or 5μMA β-(1–42) ((c), (d)) for 48h. Amyloid ﬁbrils were stained with 20μM Congo red. (a) and (c) are DIC images, while (b) and (d)
are TIRF images. Data taken from [17].
blocked by small compounds, such as nordihydroguaiaretic
acid and rifampicin [19].
The morphology of amyloid ﬁbrils formed on cell mem-
branes was visualized by total internal reﬂection ﬂuorescence
microscopy (TIRFM) [17]. TIRFM eﬀectively reduces the
backgroundﬂuorescenceandthereforeissuitableforobserv-
ing the cell surface. Fibrils were stained with Congo red.
Relatively long ﬁbrillar structures were detected around the
cell membrane for Aβ-(1–40) whereas relatively short ﬁbrils
were coassembled in the case of Aβ-(1–42) (Figure 4). TheInternational Journal of Alzheimer’s Disease 5
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Figure 5: A model for the formation of toxic amyloid ﬁbrils by
amyloid β-protein on ganglioside clusters. Aβ is essentially soluble,
and takes an unordered structure in solution. Once ganglioside
clusters are generated, Aβ binds to the clusters, forming an α-
helix-rich structure at lower protein-to-ganglioside ratios whereas
the protein changes its conformation to a β-sheet at higher ratios.
The β-sheet form facilitates the ﬁbrillization of Aβ, leading to
cytotoxicity. The amyloidogenic activity of Aβ-(1–42) is more than
10-fold that of Aβ-(1–40). Amyloid ﬁbrils formed in solution are
much less toxic.
latter observation suggests that Aβ-(1–42) ﬁbrils are more
readily fragmented. The fragmentation greatly facilitates
ﬁbril growth because ﬁbrils grow only at their ends [21].
6. Concluding Remarks
Based on the above observations, we propose a novel
model for Aβ-membrane interaction as a mechanism for
the abnormal aggregation of the protein (Figure 5). Aβ
speciﬁcally binds to a ganglioside cluster, the formation of
which is facilitated by cholesterol. The cluster can be formed
also by late endocytic dysfunction [43]. The Aβ undergoes
a conformational transition from an α-helix-rich structure
to a β-sheet-rich one with increasing protein density on
the membrane. The β-sheet form serves as a seed for the
formation of amyloid ﬁbrils, which are more toxic than
and have diﬀerent structures from those formed in solution.
Depending on ganglioside contents in the membrane, toxic
soluble oligomers may also be generated. The amyloidogenic
activityofAβ-(1–42) is more than 10-fold that of Aβ-(1–40),
although the initial interaction with gangliosides is similar
between the two proteins.
This model can explain roles of various risk factors in
the pathogenesis of AD, especially from a viewpoint of lipid
metabolism. Both the aging and the apolipoprotein E4 allele
are strong risk factors for developing AD [44]. The amount
of cholesterol in the exofacial leaﬂets of the synaptic plasma
membrane increases in aged [45]a sw e l la sa p o l i p o p r o t e i n
E4-knock-in[46]mice.GM1clusteringoccursatpresynaptic
neuritic terminals in mouse brains in an age-dependent
manner [47]. Diet-induced hypercholesterolemia accelerates
the amyloid pathology in a transgenic mouse model [48].
A link between cholesterol, Aβ, and AD has been reported
[49, 50]. Human AD brains also show abnormality in lipid
metabolism in accordance with our model [51, 52]. That
is, signiﬁcant increase in GM1 was reported in Aβ-positive
nerve terminals from the AD cortex [51], and lipid rafts
from the frontal cortex and the temporal cortex of AD brains
were also found to contain a higher concentration of GM1
comparedtoanage-matchedcontrol[52].Itshouldbenoted
that, in addition to these modulations of Aβ aggregation by
lipids, Aβ also in turn regulates lipid metabolism [53].
The 10-fold higher amyloidogenic activity of Aβ-(1–42)
is in accordance with the facts (1) that genetic mutations in
the presenilins causing early-onset AD increase the level of
Aβ-(1–42) [54] and (2) that the protein is the major species
in diﬀuse plaques, the earliest stage in the deposition of Aβ
[55].
In conclusion, in addition to other biochemical cascades,
a complex purely physicochemical cascade linked to lipid
metabolism (Figure 5) appears to be also involved in the
process of Aβ aggregation. Inhibition of one of these steps
would be a promising strategy for AD therapy.
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